SCLERODERMA CYCLOPHOSPHAMIDE OR TRANSPLANTION STUDY (SCOT)

硬皮病环磷酰胺或移植研究 (SCOT)

• 批准号: 8429091
• 负责人: KEITH M SULLIVAN
• 金额: $ 134.71万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8429091
• 关键词: Antithymoglobulin; Autologous; Autologous Transplantation; Blood; CD34 gene; Clinical Trials; Contractor; Cyclophosphamide; Data; Disease-Free Survival; Dose; Enrollment; Intravenous; Phase; Physiologic pulse; Protocols documentation; Randomized; Scleroderma; Stem cell transplant; Systemic Scleroderma; Testing; Therapeutic immunosuppression; Transplantation; Whole-Body Irradiation; open label

The contractor shall complete the clinical trial entitled ¿Protocol #: SCSSc-01 A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis¿ hereafter referred to as the ¿SCOT (Scleroderma: Cyclophosphamide or Transplantation) Trial.¿

承包商应完成题为 ¿方案编号：SCSSc-01 一项使用全身照射、环磷酰胺、ATGAM 和使用 Auto-CD34+HPC 进行自体移植与静脉脉冲环磷酰胺进行高剂量免疫抑制治疗的随机、开放标签、II/III 期多中心研究严重系统性硬化症的治疗以下简称 ¿ SCOT（硬皮病：环磷酰胺或移植）试验。¿